Predict your next investment

EyeTechCare company logo
HEALTHCARE | Medical Devices & Equipment / Therapeutic Devices
eyetechcare.com

See what CB Insights has to offer

Founded Year

2008

Stage

Series D | Alive

Total Raised

$51.76M

Last Raised

$27.22M | 6 yrs ago

About EyeTechCare

EyeTechCare is developing non-invasive therapeutic medical devices for the ophthalmology market based on High-Intensity Focused Ultrasound (HIFU), a technology that allows ambulatory and rapid treatment to be performed, thereby limiting the cost and the risk to the patient. The company's first device, EyeOP1 (R), for the treatment of glaucoma, has been undergoing clinical trials in France and Europe.

EyeTechCare Headquarter Location

2871, Avenue de l'Europe Parc d'Activités du SERMENAZ - allée C

Rillieux-la-Pape, 69140,

France

+33 (0)4 78 88 09 00

Latest EyeTechCare News

Patients accept glaucoma treatment despite ocular surface symptoms

Jan 19, 2021

Disclosures: Stalmans reports consultancies and research grants with and from Aerie, Alcon, Allergan, EyeD Pharma, EyeTechCare, Horus Pharma, Oculis, Santen, Laboratoires Théa and reports non-financial support from Théa Pharma, during the conduct of the study; personal fees from Aerie, Alcon and EyeTechCare; and personal fees and nonfinancial support from Allergan, Santen and Théa Pharma outside the submitted work. Please see the full study for all other authors’ financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio Most patients reported satisfaction with their glaucoma treatment despite a high frequency of ocular signs during ophthalmological exams and symptoms at and between instillations. Researchers published the findings in Clinical Ophthalmology. “To date, patient dissatisfaction with topical glaucoma treatments has only sporadically been studied, and the present study provides new insights in real-life data...,” Ingeborg Stalmans, MD, PhD, department of ophthalmology, Universitair Ziekenhuis Leuven, Belgium, and colleagues wrote. Stalmans and colleagues conducted an observational, multicenter, international, cross-sectional study of 793 patients (51% men; 91.5% received monotherapy) with treated, stabilized glaucoma (95.1% open angle). The outcomes of interest included patient satisfaction; ocular signs including conjunctival hyperemia, ocular surface disease (OSD) and positive conjunctival fluorescein staining; and patient reports of symptoms on and between instillations. Most (93.7%) patients reported they were satisfied or very satisfied with the tolerability of their treatment, but patients also commonly reported symptoms at time of instillation (31.4%) and between instillations (57.3%). The most common symptoms reported at instillation were pain or discomfort (21.2%) and blurred vision (7.2%). The most common symptoms reported between instillations were burning (17.4%), crusts on eyelashes (15.9%), red eye (13.1%), photophobia (12.9%), tingling (12.7%), watering (11.9%), itching (9.2%), foreign body sensation (9.0%) and dry eye sensation (5.4%). “One may hypothesize that a reason for the discrepancy between the high patient satisfaction and the high number of observed tolerance issues may reside, as already highlighted in our previous paper, in the fact that ophthalmologists insist on the importance of controlling IOP , while paying less attention to local intolerability issues,” researchers wrote. “Moreover, ophthalmologists and patients may consider the occurrence of such side effects as ‘the price to pay’ for successfully controlling their glaucoma.” There was also a high frequency of ocular signs during ophthalmological examination, including conjunctival hyperemia (32%), OSD (42.5%) and positive conjunctival fluorescein staining (10.3%). Dissatisfaction was higher among patients who reported symptoms at time of instillation (OR = 3.03) and who used tear substitutes (OR = 4.63). Other factors associated with dissatisfaction included hyperemia, OSD and a positive conjunctival fluorescein staining test (P < .001). “In conclusion, even if patients may be highly satisfied with their current treatment, most of them present [with] ocular signs and symptoms,” researchers wrote. “A treatment change should be considered in case of clinical signs or patient-reported symptoms.” Perspective

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing EyeTechCare

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

EyeTechCare is included in 1 Expert Collection, including Medical Devices.

M

Medical Devices

7,884 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

EyeTechCare Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

EyeTechCare Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.